DUBLIN--(BUSINESS WIRE)--The "The Market for Stem Cell Exosomes" report has been added to Research and Markets' offering.
Exosomes are rapidly gaining momentum as a strategy for accessing the therapeutic effects of stem cells without the risks and difficulties of administering the cells to patients. With exosome companies multiplying in number and exosome publications on the rise, it is clear that exosomes can be commercialized as therapeutic agents, diagnostic tools, research tools, cosmeceuticals, and more.
Although long overlooked, exosomes are rapidly gaining momentum as a novel strategy for accessing the therapeutic effects of stem cells without the risks and difficulties of administering the cells to patients.
Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to give credit to exosomes for a range of promising traits. Ten years ago in 2006, there were only 76 articles published about exosomes on PubMed.gov. Today, there are more than 4,400 articles published about exosomes on PubMed.gov, of which approximately 25% were released in the past year.
When exosome publications are analyzed, U.S. authors have published approximately 40% of the articles and Chinacomes in second place. When the term "exosome" is searched in the scientific literature, Dr. Susanne Gabrielsson from the Karolinska Institutet in Sweden is the leading author, with 37 articles.
On the venture capital front, there has also been a great deal of market activity. In January 2016, Exosome Diagnostics closed $60 million in Series B financing, which it followed in July 2017 with $30 million in Series C financing. Similarly,Codiak Biosciences was launched in 2016 when the MD Anderson Cancer Center joined two venture capital firms to form the company with more than $80 million in series A and B financing. On November 29, 2017, Codiak BioSciences added another $76.5 million in Series C financing. In May 2017, ExCoBio Inc. raised US $11 million in a Series A funding round.
Companies leading the charge in the area of exosome therapeutics include Anjarium Biosciences, Capricor Therapeutics, Codiak Biosciences, Creative Medical Technology Holdings, Everkine Corporation, Evox Therapeutics, Exogenus Therapeutics, Kimera Labs, ReNeuron, and Unicyte AG, a subsidiary of Fresenius Medical Care.
Numerous life science companies have also launched tools and systems to support exosome research, including Beckman Coulter, Exiqon, System Biosciences (SBI), Lonza, Thermo Fisher, Qiagen, ZenBio, and more. In particular, Lonza made aggressive investments in the sector through its May 2017 acquisition of HansaBioMed Life Sciences and investment into Exosomics.
Similarly, techniques for large-scale clinical-grade manufacture of stem cell exosomes is becoming a focal point within the industry, as highlighted by a recent partnership between RoosterBio and Exopharmand Lonza's strategic acquisitions.
To characterize this rapidly forming marketplace, we have released a 134 page market report that explores growing demand for exosome therapeutics, diagnostics, research tools, consumer care products, and manufacturing technologies. It also reveals trend rate data for exosome patents, grants, scientific publications, andclinical trials, and present social analytics from Google Trends and Google Adwords.
Claim it to:
- Identify the five market segments that compose the industry
- Reveal the market players competing in each niche
- Identify opportunities for exosome product development
- Access market size determinations and projections through 2022
Key Topics Covered:
1. Abstract
2. Research Methodology
3. Report Purpose
4. Key Characteristics of Exosomes
5. Types of Stem Cell Derived Exosomes
6. Advantages of Exosomes
7. Therapeutic Effects of Exosomes
8. Role of Stem Cell Exosomes in Cancer
9. Exosome Characterization
10. Rates of Exosome Scientific Publications (All Cell Types)
11. Trend Data
12. Social Analytics
13. Timeline of Exosome Industry Events
14. Profiles of Companies Developing Exosome Technologies
15. Companies Developing Exosome Research Products
16. SWOT Analysis (Strengths, Weaknesses, Opportunities, Threats)
17. Investment Environment
18. Market Segments
19. Market Size Determination
20. Regulatory Oversight of Exosomes
21. Exosome Conferences and Events
22. Conclusions
Appendix A - Exosome Industry Announcements
Companies Mentioned
- Anjarium Biosciences
- Avalon GloboCare Corp.
- Beckman Coulter
- Capricor Therapeutics
- Cavadis B.V.
- Cell Guidance Systems
- Codiak Biosciences
- CosmoBio USA
- Creative Medical Technologies Holdings
- Evox Therapeutics
- Exerkine Corporation
- Exiqon
- ExoCoBio Inc.
- Exogenus Therapeutics
- Exopharm
- Exosome Diagnostics
- Exosome Sciences
- Exosomics Siena SpA
- Exostemtech Co. Ltd.
- Exovita Biosciences
- Galen Lab Supplies
- Guangzhou Selaira Stem Cell Technology Co., Ltd
- HansaBioMed Life Sciences
- iZon Science
- Kimera Labs
- Lonza
- Miltenyi Biotec
- Norgen Biotek
- ReNeuron
- RoosterBio
- Unicyte AG
- ZenBio
For more information about this report visit https://www.researchandmarkets.com/research/9j47vv/stem_cell?w=4
